title: Post-Market Experience With Ocriplasmin Including Chronic Electrophysiologic Changes.
abstract: OBJECTIVE
  Intravitreal ocriplasmin has recently been used to treat vitreomacular traction, including macular holes. Recent safety concerns have arisen.
  
  
  METHODS
  A retrospective chart review was conducted of the authors' first nine patients (eight with macular holes) who were treated with intravitreal ocriplasmin. Standard clinical data were collected before and after injection, including electroretinography.
  
  
  RESULTS
  Three of the nine patients had significant electroretinogram (ERG) depression; two of these had successful closure of the macular hole. Significant ERG depression, lasting up to 15 months, occurred in one patient. The third patient had moderate ERG depression but without macular hole closure. The six remaining patients experienced no change in visual acuity or ERG.
  
  
  CONCLUSIONS
  This is one of the first reports of ocriplasmin for the treatment of macular hole including ERGs showing long-term loss of rod and cone function. Ocriplasmin successfully closed the macular hole in two of the eight patients (25%), and it was these same two patients who also experienced marked ERG depression.
authors.forename: Kent W
authors.initials: KW
authors.lastname: Small
authors.forename: Fadi S
authors.initials: FS
authors.lastname: Shaya
authors.forename: Maribel
authors.initials: M
authors.lastname: La Fontaine
mesh_terms: D004596:Electroretinography / Q000187:drug effects*; D005074:Evoked Potentials, Visual / Q000187:drug effects; D005260:Female; D005341:Fibrinolysin / Q000009:adverse effects* / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D010446:Peptide Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing; D012160:Retina / Q000503:physiopathology*; D012167:Retinal Perforations / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin